Advertisement

Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer's Disease

  • Serge Gauthier

The various etiological hypotheses for Alzheimer’s disease (AD) need to be tested in patients using designs and outcomes that are appropriate. This chapter reviews the principles of symptomatic treatment versus disease modification, the natural history of AD, and designs to slow down its progression. It should be noted that the diagnosis of AD implies first a diagnosis of dementia, followed by an assessment of its etiology. The accuracy of the clinical diagnosis of AD is in the order of 85% once dementia is clinically detected, but less than 50% in the predementia stage of amnestic mild cognitive impairment (aMCI) using clinicopathological correlations (Petersen et al., 2006).

Keywords

Alzheimer Disease Disease Modification Amnestic Mild Cognitive Impairment Nutrition Health Severe Impairment Battery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andrieu, S., Rascol, O., Lang, T., Grandjean, H., & Vellas, B. (2006). Disease modifying trials in Alzheimer's disease: Methodological and statistical issues. The Journal of Nutrition Health and Aging, 10, 116–117.Google Scholar
  2. Bodick, N., Forette, F., Hadler, D., Harvey, R. J., Leber, P., McKeith, I. G., et al. (1997). Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders 11(Suppl. 3), 50–53.PubMedGoogle Scholar
  3. Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thomson, S., Carusi, D. A., & Gombein, J. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.PubMedGoogle Scholar
  4. Doody, R. S., Winblad, B., & Jelic, V. (2004). Memantine: A glutamate antagonist for treatment of Alzheimer's disease. In S. Gauthier, P. Scheltens, & J. L. Cummings (Eds.), Alzheimer's disease and related disorders annual 2004 (pp. 137–144). London: Martin Dunitz.Google Scholar
  5. Fahn, S., Elton, R. & Members of the UPDRS development committee. (1987). United Parkinson's disease rating scale. In S. Fahn, C. Marsden, M. Golstein & D. B. Calne (Eds.), Recent development in Parkinson's disease (pp. 153–163). Florham Park, NJ: Macmillan Healthcare.Google Scholar
  6. Ferruci, L., Guralnick, J. M., & Studentski, S. (2004). Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: A consensus report. Journal of the American Geriatrics Society, 52, 625–634.CrossRefGoogle Scholar
  7. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini Mental State: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.CrossRefPubMedGoogle Scholar
  8. Galasko, D., Edland, S. D., Morris, J. C., Clark, C., Mohs, R., & Koss, E. (1995). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IX. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology, 45, 1451–1455.PubMedGoogle Scholar
  9. Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., et al. & the Alzheimer's Disease Cooperative Study. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Disease and Associated Disorders 11(Suppl. 2), S33–S39.PubMedGoogle Scholar
  10. Gauthier, S., Thal, L. J., & Rossor, M. N. (2001) The future diagnosis and management of Alzheimer's disease. In S. Gauthier, (Ed.), Clinical diagnosis and management of Alzheimer's disease (pp. 369–378). London: Martin Dunitz.Google Scholar
  11. Gauthier, S., Feldman, H., Hecker, J., Vellas, B., Ames, D., Subbiah, P., et al. (2002). Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics, 14, 389–404.CrossRefPubMedGoogle Scholar
  12. Gauthier, S., Wirth, Y., & Möbius, H. J. (2005). Effects of memantine on behavioral symptoms in Alzheimer's disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. International Journal of Geriatric Psychiatry, 20, 459–464.CrossRefPubMedGoogle Scholar
  13. Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999). Development of a functional measure for persons with Alzheimer's disease: The Disability Assessment for Dementia. The American Journal of Occupational Therapy, 53, 471–481.PubMedGoogle Scholar
  14. Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A., & Martin, R. L. (1982). A new clinical scale for the staging of dementia. The British Journal of Psychiatry, 140, 566–572.CrossRefPubMedGoogle Scholar
  15. Issa, A. M. (2003). Ethical perspectives on pharmacogenomic profiling in the drug development process. Nature Reviews, 1, 300–308.Google Scholar
  16. Leber, P. (1990). Guidelines for Clinical Evaluation of Antidementia Drugs. Washington, DC: US Food and Drug Administration.Google Scholar
  17. Lovestone, S. (2006). Biomarkers in Alzheimer's disease. The Journal of Nutrition Health and Aging, 10, 118–122.Google Scholar
  18. McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies. Neurology, 47, 425–432.PubMedGoogle Scholar
  19. Miller, E. R., & Pastor-Barriuso, R. (2005). Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine, 12, 37–46.Google Scholar
  20. Nadkarni, N. K., & Black, S. E. (2006). Cognitive outcomes. In K. Rockwood, & S. Gauthier, (Eds.), Trial designs and outcomes in dementia therapeutic research (pp. 85–112). Boca Raton, FL: Taylor & Francis.Google Scholar
  21. Panisset, M., Roudier, M., Saxton, J., Boller, F. (1994). Severe Impairment Battery: A neuropsychological test for severely demented patients. Archives of Neurology, 51, 41–45.PubMedGoogle Scholar
  22. Pennanen, C., Testa, C., Boccardi, M., Laakso, M. P., Hallikainen, M., Helkala, E. L., et al. (2006). The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: A voxel-based morphometric study. Dementia and Geriatric Cognitive Disorders, 22, 60–66.CrossRefPubMedGoogle Scholar
  23. Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., et al. (2006). Neuropathologic features of amnestic mild cognitive impairment. Archives of Neurology, 63, 665–672.CrossRefPubMedGoogle Scholar
  24. Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. The American journal of psychiatry, 141, 1356–1364.PubMedGoogle Scholar
  25. Sampaio, C. (2006). Alzheimer disease: Disease modifying trials. Where are we? Where do we need to go? A reflective paper. The Journal of Nutrition Health and Aging, 10, 113–115.Google Scholar
  26. Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., et al., for the members of the Alzheimer's Disaease Cooperative Study. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The New England Journal of Medicine, 336, 1216–1222.CrossRefPubMedGoogle Scholar
  27. Scheltens, P., & Barkhof, F. (2006). Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. The Journal of Nutrition Health and Aging, 10, 123–128.Google Scholar
  28. Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S. M., & Gergd, I. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. The Journal of American Medical Association, 291, 317–324.CrossRefGoogle Scholar
  29. Touchon, J., Portet, F., & Gauthier, S. (2006). Prevention trials in AD: One step forward? Neurology, 67, (Suppl. 3), s21–s22.PubMedGoogle Scholar
  30. Visser, P. J. (2006). Role of cognitive testing in disease modifying AD trials. The Journal of Nutrition Health and Aging, 10, 131–133.Google Scholar
  31. Whitehouse, P. J., Kittner, B., Roessner, M., Rossor, M., Sano, M., Thal, L., et al. (1998). Clinical trial designs for demonstrating disease-course-altering effects in dementia. Alzheimer Disease and Associated Disorders, 12, 281–294.CrossRefPubMedGoogle Scholar
  32. Winblad, B., Brodaty, H., Gauthier, S., Morris, J. C., Orgogozo, J.M., Rockwood, K., et al. (2001). Pharmacotherapy of Alzheimer's disease: Is there a need to redefine treatment success? International Journal of Geriatric Psychiatry, 16, 653–666.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Serge Gauthier
    • 1
  1. 1.McGill Centre for Studies in AgingMontrealCanada

Personalised recommendations